Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront
Novartis has completed the acquisition of Anthos Therapeutics in a deal valued at up to $3.1 billion, with $925 million paid upfront. Anthos, founded by Blackstone Life Sciences and Novartis in 2019, focuses on developing treatments for cardiometabolic diseases.
The company's key asset is abelacimab, a Factor XI inhibitor licensed from Novartis, currently in Phase 3 clinical trials. The drug is being tested for stroke prevention and systemic embolism in atrial fibrillation patients (LILAC-TIMI 76 trial), along with two studies for cancer-associated thrombosis (ASTER and MAGNOLIA). Trial data is expected in the second half of 2026.
Novartis ha completato l'acquisizione di Anthos Therapeutics in un affare del valore di fino a 3,1 miliardi di dollari, con 925 milioni di dollari pagati anticipatamente. Anthos, fondata da Blackstone Life Sciences e Novartis nel 2019, si concentra sullo sviluppo di trattamenti per le malattie cardiometaboliche.
Il principale asset dell'azienda è abelacimab, un inibitore del Fattore XI con licenza da Novartis, attualmente in fase 3 di sperimentazione clinica. Il farmaco è in fase di test per la prevenzione dell'ictus e dell'embolia sistemica nei pazienti con fibrillazione atriale (studio LILAC-TIMI 76), insieme a due studi per la trombosi associata a cancro (ASTER e MAGNOLIA). I dati degli studi sono attesi nella seconda metà del 2026.
Novartis ha completado la adquisición de Anthos Therapeutics en un acuerdo valorado en hasta 3,1 mil millones de dólares, con 925 millones de dólares pagados por adelantado. Anthos, fundada por Blackstone Life Sciences y Novartis en 2019, se centra en el desarrollo de tratamientos para enfermedades cardiometabólicas.
El principal activo de la compañía es abelacimab, un inhibidor del Factor XI con licencia de Novartis, que actualmente se encuentra en ensayos clínicos de Fase 3. El medicamento se está probando para la prevención de accidentes cerebrovasculares y embolia sistémica en pacientes con fibrilación auricular (ensayo LILAC-TIMI 76), junto con dos estudios para trombosis asociada al cáncer (ASTER y MAGNOLIA). Se esperan datos de los ensayos en la segunda mitad de 2026.
노바티스는 앤토스 테라퓨틱스의 인수를 완료하였으며, 거래 가치는 최대 31억 달러에 달하고, 9억 2500만 달러가 선불로 지급되었습니다. 앤토스는 블랙스톤 라이프 사이언스와 노바티스에 의해 2019년에 설립되었으며, 심혈관 대사 질환 치료제 개발에 주력하고 있습니다.
회사의 주요 자산은 아벨라시맙으로, 노바티스에서 라이선스 받은 XI 인히비터로 현재 3상 임상 시험 중입니다. 이 약물은 심방세동 환자의 뇌졸중 예방 및 전신 색전증을 위한 시험(LILAC-TIMI 76 시험)과 암 관련 혈전증에 대한 두 가지 연구(ASTER 및 MAGNOLIA)에서 시험되고 있습니다. 임상 시험 데이터는 2026년 하반기에 발표될 예정입니다.
Novartis a finalisé l'acquisition de Anthos Therapeutics dans le cadre d'un accord d'une valeur allant jusqu'à 3,1 milliards de dollars, dont 925 millions de dollars ont été payés d'avance. Anthos, fondée par Blackstone Life Sciences et Novartis en 2019, se concentre sur le développement de traitements pour les maladies cardiométaboliques.
Le principal actif de l'entreprise est abelacimab, un inhibiteur du facteur XI sous licence de Novartis, actuellement en phase 3 d'essais cliniques. Le médicament est testé pour la prévention des AVC et l'embolie systémique chez les patients atteints de fibrillation auriculaire (essai LILAC-TIMI 76), ainsi que dans deux études sur la thrombose associée au cancer (ASTER et MAGNOLIA). Les données des essais sont attendues dans la seconde moitié de 2026.
Novartis hat die Übernahme von Anthos Therapeutics abgeschlossen, wobei der Deal einen Wert von bis zu 3,1 Milliarden Dollar hat, von denen 925 Millionen Dollar im Voraus gezahlt wurden. Anthos, gegründet von Blackstone Life Sciences und Novartis im Jahr 2019, konzentriert sich auf die Entwicklung von Behandlungen für kardiometabolische Erkrankungen.
Das Hauptvermögen des Unternehmens ist abelacimab, ein Faktor-XI-Inhibitor, der von Novartis lizenziert ist und sich derzeit in klinischen Phase-3-Studien befindet. Das Medikament wird zur Schlaganfallprävention und systemischen Embolie bei Patienten mit Vorhofflimmern getestet (LILAC-TIMI 76-Studie), zusammen mit zwei Studien zu krebsassoziierter Thrombose (ASTER und MAGNOLIA). Die Studiendaten werden in der zweiten Hälfte des Jahres 2026 erwartet.
- Substantial acquisition value of $3.1B with $925M upfront payment
- Three Phase 3 clinical trials ongoing for abelacimab
- Strategic exit for Blackstone Life Sciences investment
- Potential for additional milestone-based payments
- Clinical trial results not expected until second half of 2026
- Milestone payments contingent on regulatory and commercial achievements
The deal affirms Blackstone’s vision of building companies around innovative products to meet unmet patient needs
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel Factor XI inhibitor that originated at Novartis. Abelacimab is currently in Phase 3 clinical development for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.
Transaction Details
Anthos shareholders will receive up to
Advisors
Goldman Sachs & Co. LLC acted as the lead financial advisor to Anthos. Morgan Stanley & Co. LLC also served as a financial advisor, and Goodwin Procter LLP served as legal advisor to Anthos.
About Blackstone Life Sciences
Blackstone Life Sciences (BXLS) is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has
About Anthos Therapeutics
Founded by BXLS in 2019, Anthos Therapeutics is a transformative, clinical-stage biopharmaceutical company with exclusive global rights from Novartis Pharma AG to develop, manufacture and commercialize abelacimab. BXLS was the majority investor in the company, joined by other partners including Novo Holdings. For more information about Anthos, visit the Company’s website.
About Abelacimab
Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease.
Abelacimab received a Fast Track Designation from the FDA in July 2022 for the treatment of thrombosis associated with cancer. In September 2022, abelacimab was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the expected benefits of Novartis’ acquisition of Anthos, future opportunities for the combined businesses, the development and commercialization of Anthos Therapeutics’ product candidates and the potential benefits of abelacimab. All statements, other than statements of historical facts, contained in this press release, including statements regarding the company’s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “become,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the risk that the expected benefits or synergies of the acquisition will not be realized and (ii) the risk that the milestones may not be achieved and resulting payments may not be realized, and (iii) unanticipated impact of the acquisition, including the response of business partners and competitors to the announcement of the acquisition or difficulties in employee retention. The actual financial impact of this transaction may differ from the expected financial impact described in this press release. In addition, the product candidate described in this press release is subject to all the risks inherent in the drug development process, and there can be no assurance that its development will be commercially successful. No forward-looking statement can be guaranteed. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403148958/en/
Media
Blackstone
Paula Chirhart
Paula.Chirhart@blackstone.com
Source:
FAQ
What is the total value of Novartis's acquisition of Anthos Therapeutics?
What is Anthos Therapeutics' main drug candidate and its current development stage?
When are the Phase 3 clinical trial results for abelacimab expected?
When was Anthos Therapeutics founded and by whom?
